Skip to main content
SpringerLink
Log in

Treatment of Testicular Tumours

  • Chapter
Urological Cancer Management

  • 636 Accesses

Abstract

Semen abnormalities are frequently found in patients with testicular tumours and are consistent with low volume or low sperm concentration and low motility [1, 2]. Endocrine abnormalities consistent with elevated serum HCG and estradiol, and relative decrease in FSH may also be encountered.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Notes

  1. 1.

    International Units

  2. 2.

    USP units: United States Pharmacopeia Units

References

  1. Carroll PR, Whitmore Jr WR, Herr HW, et al. Endocrine and exocrine profiles of men with testicular tumours before orchiectomy. J Urol. 1987;137(3):420–3.

    CAS  PubMed  Google Scholar 

  2. Williams DH, Karpman E, Sander JC, Spiess PE, Pisters LL, Lipshultz LI. Pretreatment semen parameters in men with cancer. J Urol. 2009;181:736–40.

    Article  PubMed  Google Scholar 

  3. Petersen PM, Skakkebaek NE, Rørth M, Giwercman A. Semen quality and reproductive hormones before and after orchiectomy in men with testicular cancer. A J Urol. 1999;161(3):822–6.

    Article  CAS  Google Scholar 

  4. Liguori G, Trombetta C, Bucci S, Benvenuto S, Amodeo A, Ocello G, Belgrano E. Semen quality before and after orchiectomy in men with testicular cancer. Arch Ital Urol Androl. 2008;80(3):99–102.

    PubMed  Google Scholar 

  5. Donohue JP, Foster RS, Rowland RG, Bihrle R, Jones R, Geier G. Nerve sparing retroperitoneal lymphadenectomy with preservation of ejaculation. J Urol. 1990;144:287–92.

    CAS  PubMed  Google Scholar 

  6. Auroux M, Dulioust EJ, Nawar NN, Yacoub SG, Mayaux MJ, Schwartz D, David G. Antimitotic drugs in the male rat. Behavioral abnormalities in the second generation. J Androl. 1988;9:153–9.

    CAS  PubMed  Google Scholar 

  7. Auroux M, Dulioust E, Selva J, Rince P. Cyclophosphamide in the F0 male rat: physical and behavioral changes in three successive adult generations. Mutat Res. 1990;229:189–200.

    Article  CAS  PubMed  Google Scholar 

  8. Senturia YD, Peckham CS. Children fathered by men treated with chemotherapy for testicular cancer. Eur J Cancer. 1990;26(4):429–32.

    Article  CAS  PubMed  Google Scholar 

  9. Dodds L, Marrett LD, Tomkins DJ, Green B, Sherman G. Case-control study of congenital anomalies in children of cancer patients. BMJ. 1993;307(6897):164–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  10. Schmoll HJ, Souchon R, Krege S, et al.; European Germ Cell Cancer Consensus Group. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol. 2004;15(9):1377–99.

    Google Scholar 

  11. Rampaul MS, Hosking SW. Testicular torsion: most delay occurs outside hospital. Ann R Coll Surg Engl. 1998;80(3):169–72.

    PubMed Central  CAS  PubMed  Google Scholar 

  12. Cattolica EV, Karol JB, Rankin KN, Klein RS. High testicular salvage rate in torsion of the spermatic cord. J Urol. 1982;128(1):66–8.

    CAS  PubMed  Google Scholar 

  13. McNamara ER, Madden-Fuentes RJ, Routh JC, Rouse D, Madden JF, Wiener JS, Rushton Jr HG, Ross SS. Evaluation of cold ischemia for preservation of testicular function during partial orchiectomy in the rat model. J Pediatr Urol. 2014;10(4):593–7.

    Article  PubMed  Google Scholar 

  14. Reddy BV, Sivakanth A, Naveen Babu G, Swamyvelu K, Basavana Goud YG, Madhusudhana BA, Challa VR. Role of chemotherapy prior to orchiectomy in metastatic testicular cancer—is testis really a sanctuary site? Ecancermedicalscience. 2014;8:407.

    PubMed Central  PubMed  Google Scholar 

  15. Geldart TR, Simmonds PD, Mead GM. Orchidectomy after chemotherapy for patients with metastatic testicular germ cell cancer. BJU Int. 2002;90(4):451–5.

    Article  CAS  PubMed  Google Scholar 

  16. Ondrus D, Hornák M, Breza J, Mat’oska J, Schnorrer M, Belan V, Kausitz J. Delayed orchiectomy after chemotherapy in patients with advanced testicular cancer. Int Urol Nephrol. 2001;32(4):665–7.

    Article  CAS  PubMed  Google Scholar 

  17. Durand X, Rigaud J, Avancès C, Les membres du CCAFU, et al. CCAFU recommendations 2013: testicular germ cell cancer. Prog Urol. 2013;23 Suppl 2:S145–60.

    Article  PubMed  Google Scholar 

  18. Heidenreich A, Weissbach L, Höltl W, Albers P, Kliesch S, Köhrmann KU, DIeckmann KP, German Testicular Cancer Study Group. Organ sparing surgery for malignant germ cell tumour of the testis. J Urol. 2001;166(6):2161–5.

    Article  CAS  PubMed  Google Scholar 

  19. Albers P, Göll A, Bierhoff E, et al. Clinical course and histopathologic risk factor assessment in patients with bilateral testicular germ cell tumours. Urology. 1999;54(4):714–8.

    Article  CAS  PubMed  Google Scholar 

  20. Stang A, Jansen L, Trabert B, Rusner C, Eberle A, Katalinic A, Emrich K, Holleczek B, Brenner H, GEKID Cancer Survival Working Group. Survival after a diagnosis of testicular germ cell cancers in Germany and the United States, 2002-2006: a high resolution study by histology and age. Cancer Epidemiol. 2013;37(4):492–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K, Horwich A, Laguna MP, European Association of Urology. EAU guidelines on testicular cancer: 2011 update. Eur Urol. 2011;60(2):304–19. doi:10.1016/j.eururo.2011.05.038. Epub 2011 May 25.

    Article  PubMed  Google Scholar 

  22. Oliver RT, Mead GM, Rustin GJ, Joffe JK, Aass N, Coleman R, Gabe R, Pollock P, Stenning SP. Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214). J Clin Oncol. 2011;29(8):957–62.

    Article  CAS  PubMed  Google Scholar 

  23. Porcaro AB, Antoniolli SZ, Schiavone D, Maffei N, Bassetto MA, Curti P. Management of clinical stage I testicular pure seminoma. Report on 42 patients and review of the literature. Arch Ital Urol Androl. 2002;74(2):77–80.

    PubMed  Google Scholar 

  24. Read G, Stenning SP, Cullen MH, Parkinson MC, Horwich A, Kaye SB, Cook PA, Medical Research Council Testicular Tumours Working Party. Medical Research Council prospective study of surveillance for stage I testicular teratoma. J Clin Oncol. 1992;10(11):1762–8.

    CAS  PubMed  Google Scholar 

  25. Heidenreich A, Albers P, Hartmann M, et al. Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumours of the testis: experience of the German Testicular Cancer Study Group. J Urol. 2003;169:1710.

    Article  PubMed  Google Scholar 

  26. Stephenson AJ, Bosl GJ, Motzer RJ, Kattan MW, Stasi J, Bajorin DF, Sheinfeld J. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome. J Clin Oncol. 2005;23(12):2781–8.

    Article  PubMed  Google Scholar 

  27. Hartmann JT, Fels LM, Knop S, Stolt H, Kanz L, Bokemeyer C. A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumours. Invest New Drugs. 2000;18(3):281–9.

    Article  CAS  PubMed  Google Scholar 

  28. Joel SP, Shah R, Clark PI, Slevin ML. Predicting etoposide toxicity: relationship to organ function and protein binding. J Clin Oncol. 1996;14(1):257–67.

    CAS  PubMed  Google Scholar 

  29. Sleijfer S. Bleomycin-induced pneumonitis. Chest. 2001;120(2):617–24.

    Article  CAS  PubMed  Google Scholar 

  30. O’Sullivan JM, Huddart RA, Norman AR, Nicholls J, Dearnaley DP, Horwich A. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol. 2003;14(1):91–6.

    Article  PubMed  Google Scholar 

  31. Tashiro M, Izumikawa K, Yoshioka D, et al. Lung fibrosis 10 years after cessation of bleomycin therapy. Tohoku J Exp Med. 2008;216(1):77–80.

    Article  PubMed  Google Scholar 

  32. Matthews JH. Pulmonary toxicity of ABVD chemotherapy and G-CSF in Hodgkin’s disease: possible synergy. Lancet. 1993;342:988.

    Article  CAS  PubMed  Google Scholar 

  33. Williams S, Birch R, Einhorn LH, et al. Treatment of dissiminated germ cell tumours with cisplatin, bleomycin and either vinblastin or etoposide. N Engl J Med. 1987;316(23):1435–40.

    Article  CAS  PubMed  Google Scholar 

  34. de Wit R, Roberts JT, Wilkinson PM, de Mulder PH, Mead GM, Fosså SD, Cook P, de Prijck L, Stenning S, Collette L. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer. Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol. 2001;19(6):1629–40.

    PubMed  Google Scholar 

  35. Horwich A, Peckham MJ. Transient tumour marker elevation following chemotherapy for germ cell tumours of the testis. Cancer Treat Rep. 1986;70(11):1329–31.

    CAS  PubMed  Google Scholar 

  36. de Wit R, Collette L, Sylvester R, de Mulder PH, Sleijfer DT, ten Bokkel Huinink WW, Kaye SB, van Oosterom AT, Boven E, Stoter G. Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance. Br J Cancer. 1998;78(10):1350–5.

    Article  PubMed Central  PubMed  Google Scholar 

  37. Peckham MJ, Horwich A, Hendry WF. Advanced seminoma: treatment with cis-platinum-basedcombination chemotherapy or carboplatin (JM8). Br J Cancer. 1985;52:7–13.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  38. Fizazi K, Tjulandin S, Salvioni R, et al. Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumours: prognostic factors and role of postsurgery chemotherapy–results from an international study group. J Clin Oncol. 2001;19(10):2647–57.

    CAS  PubMed  Google Scholar 

  39. Fizazi K, Oldenburg J, Dunant A. Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumours (NSGCT): results of the sCR2 international study. Ann Oncol. 2008;19(2):259–64.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Urology Department, The Royal Hospital, Muscat, Oman

    Qais Mohamed Al-Hooti & Said Abdallah Al-Mamari

Authors
  1. Qais Mohamed Al-Hooti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Said Abdallah Al-Mamari
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Said Abdallah Al-Mamari .

Editor information

Editors and Affiliations

  1. Urology Department, The Royal Hospital, Muscat, Oman

    Said Abdallah Al-Mamari

  2. Urology Department, The Royal Hospital, Muscat, Oman

    Salim Said Al-Busaidy

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Al-Hooti, Q.M., Al-Mamari, S.A. (2015). Treatment of Testicular Tumours. In: Al-Mamari, S., Al-Busaidy, S. (eds) Urological Cancer Management. Springer, Cham. https://doi.org/10.1007/978-3-319-16301-7_22

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-16301-7_22

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-16300-0

  • Online ISBN: 978-3-319-16301-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation